Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Return on Equity (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Return on Equity for 14 consecutive years, with 0.37% as the latest value for Q1 2026.

  • For Q1 2026, Return on Equity fell 81.0% year-over-year to 0.37%; the TTM value through Mar 2026 reached 0.37%, down 81.0%, while the annual FY2025 figure was 0.3%, 87.0% down from the prior year.
  • Return on Equity hit 0.37% in Q1 2026 for Agios Pharmaceuticals, down from 0.33% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.59% in Q3 2024 and bottomed at 0.52% in Q2 2024.
  • Average Return on Equity over 5 years is 0.06%, with a median of 0.12% recorded in 2023.
  • Year-over-year, Return on Equity crashed -143bps in 2022 and then skyrocketed 98bps in 2025.
  • Agios Pharmaceuticals' Return on Equity stood at 0.0% in 2022, then plummeted by -11596bps to 0.42% in 2023, then soared by 201bps to 0.42% in 2024, then crashed by -179bps to 0.33% in 2025, then decreased by -10bps to 0.37% in 2026.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.37%, 0.33%, and 0.3% for Q1 2026, Q4 2025, and Q3 2025 respectively.